Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.43 |
| ▸ | LPL | P06858 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | F11 | P03951 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982315 | 0.81 | DGAT1 (0.47) | DGAT1LIPGLPLCA1CA2 | |
| SCHEMBL21838822 | 0.78 | DGAT1 (0.59) | DGAT1LIPGLPLCA1CA2 | |
| SCHEMBL17734224 | 0.77 | LIPG (0.49) | DGAT1LIPGLPLCA1CA2 | |
| SCHEMBL2218979 | 0.76 | KMT2A (0.44) | — | |
| SCHEMBL2223083 | 0.74 | MAPT (0.47) | — | |
| SCHEMBL23647510 | 0.73 | AAK1 (0.46) | DGAT1LIPGLPLCA1CA2 | |
| SCHEMBL10458 | 0.73 | DGAT1 (0.53) | DGAT1LIPGLPLCA1CA2 | |
| SCHEMBL2012047 | 0.73 | F11 (0.46) | DGAT1LIPGLPLCA1CA2 | |
| SCHEMBL21383621 | 0.73 | LIPG (0.54) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL23357790 | 0.72 | DGAT1 (0.52) | DGAT1LIPGLPLCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2334636-A2 | HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032147-A2 | HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HCAR1, H1-0, HDAC1 | DGAT1 3319/4885LIPG 3741/4885LPL 3942/4885 |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | HCAR1, HDAC1, H1-0 | DGAT1 3136/4885LIPG 3795/4885LPL 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.